Background:Given the recent updates in cancer burden estimates by GLOBOCAN 2022,this study was undertaken to provide pertinent perspectives within the context of the Human Development Index(HDI)and major world economi...Background:Given the recent updates in cancer burden estimates by GLOBOCAN 2022,this study was undertaken to provide pertinent perspectives within the context of the Human Development Index(HDI)and major world economies.Methods:Datasets sourced from GLOBOCAN encompassed cancer cases and deaths across all cancer types in 2022,alongside projections up to 2050.Cancer incidences and deaths of the top 10 cancers within China and four distinct HDI-classified regions were compared using descriptive analyses.Age-standardized incidence rates(ASIRs)and mortality rates(ASMRs)worldwide for the most prevalent cancers in 2022 across ten largest economies and four-tier HDIs were examined.The top five cancer types concerning both incidence and mortality in China were delineated by sex and age group.Results:In males,prostate cancer predominated in countries with low,high(except China),and very high HDI.Prostate and liver cancers were prominent causes of death in countries with low HDI.In females,breast and cervical cancers predominated in countries with low-to-medium HDI.Lung and colorectal cancer incidence and deaths increased with high HDI for both sexes.ASIRs and ASMRs for breast,prostate,lung,and colorectal cancers in the top 10 economies were higher than the global average.However,liver,stomach,and cervical cancers in most Western countries exhibited lower rates.In China,hematologic malignancies(43%)were prevalent among children aged 0-14 years,whereas thyroid cancer led among adolescents and young adults aged 15-39 years.Regarding incidence and mortality,lung cancer predominated for individuals over 40 years,except for females aged 40-59 years,in whom breast cancer predominated.Projected trends indicated substantial increases in new cancer cases(76.6%)and deaths(89.7%)over the next three decades.Conclusions:Infection-and poverty-related cancer burdens are offset by increased prostate,breast,colorectal,and lung cancer incidence associated with rapid societal and economic transitions.Cancer incidence and mortality patterns in China feature characteristics of developed and developing countries,necessitating tailored,evidence-based,and comprehensive strategies for effective cancer prevention and control.展开更多
[目的]探讨术前纤维蛋白原-前白蛋白比值指数(fibrinogen-prealbumin ratio index,FPRI)联合血小板-淋巴细胞比值(platelet-lymphocyte ratio,PLR)评分对根治性切除术结直肠癌患者的预后价值。[方法]对249例手术结直肠癌患者的术前FPRI...[目的]探讨术前纤维蛋白原-前白蛋白比值指数(fibrinogen-prealbumin ratio index,FPRI)联合血小板-淋巴细胞比值(platelet-lymphocyte ratio,PLR)评分对根治性切除术结直肠癌患者的预后价值。[方法]对249例手术结直肠癌患者的术前FPRI、纤维蛋白原-白蛋白比值指数(fibrinogen-albumin ratio index,FARI)、中性粒细胞-淋巴细胞比值(neutrophil-lymphocyte ratio,NLR)和PLR进行分析。通过受试者工作特征(receiver operating characteristics,ROC)曲线分析确定各指标的最佳截断值,并通过Kaplan-Meier曲线和Cox回归模型评估它们对总生存期(overall suvival,OS)、无病生存期(disease-free survival,DFS)的预后价值。[结果]ROC曲线结果显示,FPRI、FARI、NLR和PLR的最佳截断值分别为11.8%、8.2%、3.26和158.65。单因素分析结果显示,FPRI、FARI、NLR和PLR均是CRC患者的预后影响因素(P均<0.05)。FPRI对OS和DFS的预测价值优于FARI、NLR和PLR (OS:AUC_(FPRI)=0.658,AUC_(FARI)=0.581,AUC_(NLR)=0.536,AUC_(PLR)=0.588;DFS:AUC_(FPRI)=0.618,AUC_(FARI)=0.545,AUC_(NLR)=0.511,AUC_(PLR)=0.549)。多因素分析结果显示,高FPRI、高PLR和FPRI联合PLR评分高是患者OS和DFS的独立危险影响因素(P均<0.001)。[结论]FPRI和PLR均可预测根治性切除术结直肠癌患者的预后,且两者联合比单独FPRI和PLR效果更优。展开更多
文摘Background:Given the recent updates in cancer burden estimates by GLOBOCAN 2022,this study was undertaken to provide pertinent perspectives within the context of the Human Development Index(HDI)and major world economies.Methods:Datasets sourced from GLOBOCAN encompassed cancer cases and deaths across all cancer types in 2022,alongside projections up to 2050.Cancer incidences and deaths of the top 10 cancers within China and four distinct HDI-classified regions were compared using descriptive analyses.Age-standardized incidence rates(ASIRs)and mortality rates(ASMRs)worldwide for the most prevalent cancers in 2022 across ten largest economies and four-tier HDIs were examined.The top five cancer types concerning both incidence and mortality in China were delineated by sex and age group.Results:In males,prostate cancer predominated in countries with low,high(except China),and very high HDI.Prostate and liver cancers were prominent causes of death in countries with low HDI.In females,breast and cervical cancers predominated in countries with low-to-medium HDI.Lung and colorectal cancer incidence and deaths increased with high HDI for both sexes.ASIRs and ASMRs for breast,prostate,lung,and colorectal cancers in the top 10 economies were higher than the global average.However,liver,stomach,and cervical cancers in most Western countries exhibited lower rates.In China,hematologic malignancies(43%)were prevalent among children aged 0-14 years,whereas thyroid cancer led among adolescents and young adults aged 15-39 years.Regarding incidence and mortality,lung cancer predominated for individuals over 40 years,except for females aged 40-59 years,in whom breast cancer predominated.Projected trends indicated substantial increases in new cancer cases(76.6%)and deaths(89.7%)over the next three decades.Conclusions:Infection-and poverty-related cancer burdens are offset by increased prostate,breast,colorectal,and lung cancer incidence associated with rapid societal and economic transitions.Cancer incidence and mortality patterns in China feature characteristics of developed and developing countries,necessitating tailored,evidence-based,and comprehensive strategies for effective cancer prevention and control.